Alzheimers & Dementia

Article	Citations
2021 Alzheimer's disease facts and figures	1699
2022 Alzheimer's disease facts and figures	1346
2023 Alzheimer's disease facts and figures	1153
Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020–2060)	503
Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019	342
Global estimates on the number of persons across the Alzheimer's disease continuum	263
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease	235
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease	198
Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study	189
COVID‐19 and dementia: Analyses of risk, disparity, and outcomes from electronic health records in the US	181
Changes in cognitive functioning after COVID‐19: A systematic review and meta‐analysis	181
The chronic neuropsychiatric sequelae of COVID‐19: The need for a prospective study of viral impact on brain functioning	149
Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research	141
The role of mitochondrial dysfunction in Alzheimer's disease pathogenesis	128
Alzheimer's‐like signaling in brains of COVID‐19 patients	120
Prevalence of cerebral amyloid angiopathy: A systematic review and meta‐analysis	119
Acute systemic inflammation exacerbates neuroinflammation in Alzheimer's disease: IL‐1β drives amplified responses in primed astrocytes and neuronal network dysfunction	116
Cognitive impairment in sporadic cerebral small vessel disease: A systematic review and meta‐analysis	112
Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities	112
Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease	111
Characterization of pre‐analytical sample handling effects on a panel of Alzheimer's disease–related blood‐based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) wor	109
The worldwide costs of dementia in 2019	104
World Alzheimer Report 2019: Attitudes to dementia, a global survey	102
The impact of diabetes on cognitive impairment and its progression to dementia	99
Comparison of serum neurodegenerative biomarkers among hospitalized COVID‐19 patients versus non‐COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer's dementia	99

The estimation of the global prevalence of dementia from 1990‐2019 and forecasted prevalence through 2050: An analysis for the Global Burden of Disease (GBD) study 2019	97
Midlife vascular risk factors and risk of incident dementia: Longitudinal cohort and Mendelian randomization analyses in the UK Biobank	95
Gait variability across neurodegenerative and cognitive disorders: Results from the Canadian Consortium of Neurodegeneration in Aging (CCNA) and the Gait and Brain Study	93
Regional brain iron associated with deterioration in Alzheimer's disease: A large cohort study and theoretical significance	91
Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis	89
Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tau	88
Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel	88
An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum	85
Diagnostic criteria for apathy in neurocognitive disorders	85
White matter hyperintensity topography in Alzheimer's disease and links to cognition	85
Synaptic density and cognitive performance in Alzheimer's disease: A PET imaging study with [11C]UCB‐J	83
Plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross‐sectional and longitudinal study in the AIBL cohort	79
Multimorbidity burden and dementia risk in older adults: The role of inflammation and genetics	78
Plasma and CSF biomarkers in a memory clinic: Head‐to‐head comparison of phosphorylated tau immunoassays	77
Large‐scale plasma proteomic profiling identifies a high‐performance biomarker panel for Alzheimer's disease screening and staging	76
Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance	75
Integrative metabolomics‐genomics approach reveals key metabolic pathways and regulators of Alzheimer's disease	75
Black and White individuals differ in dementia prevalence, risk factors, and symptomatic presentation	75
Associations of loneliness with risk of Alzheimer's disease dementia in the Framingham Heart Study	74
Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis	73
Dementia is an age‐independent risk factor for severity and death in COVID‐19 inpatients	72
Dementia in Latin America: Paving the way toward a regional action plan	72
Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease	71
Toward a theory‐based specification of non‐pharmacological treatments in aging and dementia: Focused reviews and methodological recommendations	69
2024 Alzheimer's disease facts and figures	66
An accurate fully automated panel of plasma biomarkers for Alzheimer's disease	64
ENGAGE and EMERGE: Truth and consequences?	62
The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau	62
The AHEAD 3‐45 Study: Design of a prevention trial for Alzheimer's disease	60
Age‐related calcium dysregulation linked with tau pathology and impaired cognition in non‐human primates	58
Whole‐genome sequencing reveals new Alzheimer's disease–associated rare variants in loci related to synaptic function and neuronal development	57
Diversity of transcriptomic microglial phenotypes in aging and Alzheimer's disease	57
Consideration of sex and gender in Alzheimer's disease and related disorders from a global perspective	57
Diversity in Alzheimer's disease drug trials: The importance of eligibility criteria	57
Mediterranean and Western diet effects on Alzheimer's disease biomarkers, cerebral perfusion, and cognition in mid‐life: A randomized trial	57
Traditional Chinese medicine for dementia	56
Dementia in Africa: Current evidence, knowledge gaps, and future directions	54
Plasma IL‐12/IFN‐γ axis predicts cognitive trajectories in cognitively unimpaired older adults	54
Emerge and Engage topline results: Phase 3 studies of aducanumab in early Alzheimer’s disease	54
Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort	53
MRI‐assessed locus coeruleus integrity is heritable and associated with multiple cognitive domains, mild cognitive impairment, and daytime dysfunction	52
Daytime napping and Alzheimer's dementia: A potential bidirectional relationship	51
The structural and social determinants of Alzheimer's disease related dementias	51
Potential role of chitinase‐3‐like protein 1 (CHI3L1/YKL‐40) in neurodegeneration and Alzheimer's disease	50
Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease	50
Plasma hydrogen sulfide: A biomarker of Alzheimer's disease and related dementias	50
Stroke and dementia, leading causes of neurological disability and death, potential for prevention	49
MarkVCID cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols	49
Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification	49
The economic cost of delirium: A systematic review and quality assessment	49

A novel tau‐based rhesus monkey model of Alzheimer's pathogenesis	48
Concomitant neurodegenerative pathologies contribute to the transition from mild cognitive impairment to dementia	47
Prevalence of dementia in India: National and state estimates from a nationwide study	47
Mild cognitive impairment among rural‐dwelling older adults in China: A community‐based study	46
Current directions in tau research: Highlights from Tau 2020	46
Validity of the 2014 traumatic encephalopathy syndrome criteria for CTE pathology	45
Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community‐engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4	44
MarkVCID cerebral small vessel consortium: II. Neuroimaging protocols	44
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup	42
ABCA7 and the altered lipidostasis hypothesis of Alzheimer's disease	42
The costs of developing treatments for Alzheimer's disease: A retrospective exploration	41
Medical comorbidities and ethnicity impact plasma Alzheimer's disease biomarkers: Important considerations for clinical trials and practice	41
Distinct effects of beta‐amyloid and tau on cortical thickness in cognitively healthy older adults	41
Head injury and 25‐year risk of dementia	41
Characterizing plasma NfL in a community‐dwelling multi‐ethnic cohort: Results from the HABLE study	41
Bayes analysis supports null hypothesis of anti‐amyloid beta therapy in Alzheimer's disease	40
Plasma P‐tau181 to Aβ42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease	40
Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers	40
Impact of COVID‐19 on the Onset and Progression of Alzheimer's Disease and Related Dementias: A Roadmap for Future Research	40
Increased APOE ε4 expression is associated with the difference in Alzheimer's disease risk from diverse ancestral backgrounds	39
Speech‐in‐noise hearing impairment is associated with an increased risk of incident dementia in 82,039 UK Biobank participants	38
A critical appraisal of tau‐targeting therapies for primary and secondary tauopathies	38
Association of plasma biomarkers, p‐tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long‐term clinical Alzheimer's disease risk: Results from a prospective coho	38
Detection of Alzheimer's disease amyloid beta 1‐42, p‐tau, and t‐tau assays	37
The effect of adherence on cognition in a multidomain lifestyle intervention (FINGER)	37
Alzheimer's disease biomarkers in Black and non‐Hispanic White cohorts: A contextualized review of the evidence	37
Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia	37
Reactive or transgenic increase in microglial TYROBP reveals a TREM2‐independent TYROBP–APOE link in wild‐type and Alzheimer's‐related mice	37
Plasma proteins, cognitive decline, and 20‐year risk of dementia in the Whitehall II and Atherosclerosis Risk in Communities studies	37
Early dementia diagnosis, MCI‐to‐dementia risk prediction, and the role of machine learning methods for feature extraction from integrated biomarkers, in particular for EEG signal analysis	37
Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve	37
Expectations and clinical meaningfulness of randomized controlled trials	36
Alzheimer's disease alters oligodendrocytic glycolytic and ketolytic gene expression	36
Water exchange rate across the blood‐brain barrier is associated with CSF amyloid‐β 42 in healthy older adults	35
Suicide risk in first year after dementia diagnosis in older adults	35
Sex differences in dementia and response to a lifestyle intervention: Evidence from Nordic population‐based studies and a prevention trial	35
The Longitudinal Early‐onset Alzheimer's Disease Study (LEADS): Framework and methodology	35
COVID‐19 breakthrough infections and hospitalizations among vaccinated patients with dementia in the United States between December 2020 and August 2021	34
Mild behavioral impairment is associated with progression to Alzheimer's disease: A clinicopathological study	34
APOE alleles’ association with cognitive function differs across Hispanic/Latino groups and genetic ancestry in the study of Latinos‐investigation of neurocognitive aging (HCHS/SOL)	34
State‐of‐the‐art of lumbar puncture and its place in the journey of patients with Alzheimer's disease	33
Effects of cocoa extract and a multivitamin on cognitive function: A randomized clinical trial	33
Addressing the disparities in dementia risk, early detection and care in Latino populations: Highlights from the second Latinos & Alzheimer's Symposium	33
Tau pathologies mediate the association of blood pressure with cognitive impairment in adults without dementia: The CABLE study	33
Early prevention of cognitive impairment in the community population: The Beijing Aging Brain Rejuvenation Initiative	33
Differences between blood and cerebrospinal fluid glial fibrillary Acidic protein levels: The effect of sample stability	32
Biphasic cortical macro‐ and microstructural changes in autosomal dominant Alzheimer's disease	32
Biofluid‐based biomarkers for Alzheimer's disease–related pathologies: An update and synthesis of the literature	32
Identification of the Aβ37/42 peptide ratio in CSF as an improved Aβ biomarker for Alzheimer's disease	32
In situ spatial glycomic imaging of mouse and human Alzheimer's disease brains	32
Mitochondrial ROS control neuronal excitability and cell fate in frontotemporal dementia	32
Effect of periodontal treatment on preclinical Alzheimer's disease—Results of a trial emulation approach	32
Decoding perineuronal net glycan sulfation patterns in the Alzheimer's disease brain	32
Clinical performance and robustness evaluation of plasma amyloid‐β42/40 prescreening	32
Rural‐urban differences in diagnostic incidence and prevalence of Alzheimer's disease and related dementias	32
C‐reactive protein levels and risk of dementia—Observational and genetic studies of 111,242 individuals from the general population	31
Test‐retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models	31
Midlife lipid and glucose levels are associated with Alzheimer's disease	31
Association of Life's Simple 7 with incident dementia and its modification by the apolipoprotein E genotype	31
Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes	31
Slowing gait speed precedes cognitive decline by several years	31
Anosmia, mild cognitive impairment, and biomarkers of brain aging in older adults	31
Brain health: Key to health, productivity, and well‐being	30
Risk factors for dementia in Brazil: Differences by region and race	30
Amyloid‐beta misfolding and GFAP predict risk of clinical Alzheimer's disease diagnosis within 17 years	30
Microglial INPP5D limits plaque formation and glial reactivity in the PSAPP mouse model of Alzheimer's disease	30
Quantifying dementia prevention potential in the FINGER randomized controlled trial using the LIBRA prevention index	30
Comparative analytical performance of multiple plasma Aβ42 and Aβ40 assays and their ability to predict positron emission tomography amyloid positivity	30
Association of cardiovascular risk burden with risk of dementia and brain pathologies: A population‐based cohort study	30
Equivalence of plasma p‐tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease	30
Late‐life physical activity relates to brain tissue synaptic integrity markers in older adults	30
Aducanumab: Appropriate use recommendations	30
Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials	29
Impact of increased APP gene dose in Down syndrome and the Dp16 mouse model	29
Tau phosphorylation sites serine202 and serine396 are differently altered in chronic traumatic encephalopathy and Alzheimer's disease	29
Hypertension and hyperhomocysteinemia as modifiable risk factors for Alzheimer's disease and dementia: New evidence, potential therapeutic strategies, and biomarkers	29
Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease	29
Blood extracellular vesicles carrying synaptic function‐ and brain‐related proteins as potential biomarkers for Alzheimer's disease	29
Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease	29
Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings	29

Cardiometabolic multimorbidity accelerates cognitive decline and dementia progression	29
White matter hyperintensities in Alzheimer's disease: Beyond vascular contribution	29
A combination model of AD biomarkers revealed by machine learning precisely predicts Alzheimer's dementia: China Aging and Neurodegenerative Initiative (CANDI) study	28
Unhealthy foods may attenuate the beneficial relation of a Mediterranean diet to cognitive decline	28
TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels	28
Dementia with Lewy bodies: Impact of co‐pathologies and implications for clinical trial design	28
Global, regional, and national trends of dementia incidence and risk factors, 1990–2019: A Global Burden of Disease study	28
Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease	28
CSF biomarkers and plasma p‐tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design	27
	27
Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline	27
Neurodegeneration and astrogliosis in the entorhinal cortex in Alzheimer's disease: Stereological layer‐specific assessment and proteomic analysis	27
ATN incorporating cerebrospinal fluid neurofilament light chain detects frontotemporal lobar degeneration	27
The BIN1 rs744373 Alzheimer's disease risk SNP is associated with faster Aβ‐associated tau accumulation and cognitive decline	27
Elevated plasma neurofilament light predicts a faster rate of cognitive decline over 5 years in participants with objectively‐defined subtle cognitive decline and MCI	27
Effects of a ketogenic and low‐fat diet on the human metabolome, microbiome, and foodome in adults at risk for Alzheimer's disease	26
Integrative functional genomic analysis of intron retention in human and mouse brain with Alzheimer's disease	26
Acute sleep loss decreases CSF‐to‐blood clearance of Alzheimer's disease biomarkers	26
Hypothesis: JNK signaling is a therapeutic target of neurodegenerative diseases	26
Characteristics of subjective cognitive decline associated with amyloid positivity	26
Increased β‐site APP cleaving enzyme 1‐mediated insulin receptor cleavage in type 2 diabetes mellitus with cognitive impairment	26
White matter hyperintensities and longitudinal cognitive decline in cognitively normal populations and across diagnostic categories: A meta‐analysis, systematic review, and recommendations for future	26
Lower serum testosterone concentrations are associated with a higher incidence of dementia in men: The UK Biobank prospective cohort study	26
Systematic in silico analysis of clinically tested drugs for reducing amyloid‐beta plaque accumulation in Alzheimer's disease	26
Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe	26
Interpretable machine learning for dementia: A systematic review	26
Open Peer Commentary to “Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019”	26
Cerebrospinal fluid biomarker panel of synaptic dysfunction in Alzheimer's disease and other neurodegenerative disorders	26
Cerebral small vessel disease burden and cognitive and functional outcomes after stroke: A multicenter prospective cohort study	25
Generalizability of findings from a clinical sample to a community‐based sample: A comparison of ADNI and ARIC	25
Ophthalmic conditions associated with dementia risk: The Cardiovascular Health Study	25
Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview	25
Quantifying progression in primary progressive aphasia with structural neuroimaging	25
Association of life‐course depression with the risk of dementia in late life: A nationwide twin study	25
Brain structures and networks responsible for stimulation‐induced memory flashbacks during forniceal deep brain stimulation for Alzheimer's disease	25
Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia	25
Risk of Alzheimer's disease and related dementia by sex and race/ethnicity: The Multiethnic Cohort Study	24
Reduced synchrony in alpha oscillations during life predicts post mortem neurofibrillary tangle density in early‐onset and atypical Alzheimer's disease	24
Genome‐wide association and multi‐omics studies identify MGMT as a novel risk gene for Alzheimer's disease among women	24
Plasma amyloid beta predicts conversion to dementia in subjects with mild cognitive impairment: The BALTAZAR study	24
Associations of grip strength, walking pace, and the risk of incident dementia: A prospective cohort study of 340212 participants	24
The P522R protective variant of PLCG2 promotes the expression of antigen presentation genes by human microglia in an Alzheimer's disease mouse model	24
Development and validation of the Uniform Data Set (v3.0) executive function composite score (UDS3‐EF)	24
Estimating the global mortality from Alzheimer’s disease and other dementias: A new method and results from the Global Burden of Disease study 2019	24
Expected wait times for access to a disease‐modifying Alzheimer's treatment in the United States	24
Pathogenesis of sporadic Alzheimer's disease by deficiency of NMDA receptor subunit GluN3A	24
Unraveling the heterogeneity in Alzheimer's disease progression across multiple cohorts and the implications for data‐driven disease modeling	23
Global incidence of young‐onset dementia: A systematic review and meta‐analysis	23
Associations among vascular risk factors, neuroimaging biomarkers, and cognition: Preliminary analyses from the Multi‐Ethnic Study of Atherosclerosis (MESA)	23
Mendelian randomization highlights causal association between genetically increased C‐reactive protein levels and reduced Alzheimer's disease risk	23
Automated detection of mild cognitive impairment and dementia from voice recordings: A natural language processing approach	23
Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum	23
Plasma Aβ42/Aβ40 and phospho‐tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease	23
Characterization of dementia with Lewy bodies (DLB) and mild cognitive impairment using the Lewy body dementia module (LBD‐MOD)	23
Strategic white matter hyperintensity locations for cognitive impairment: A multicenter lesion‐symptom mapping study in 3525 memory clinic patients	23
APP accumulates with presynaptic proteins around amyloid plaques: A role for presynaptic mechanisms in Alzheimer's disease?	23
The PASTIS trial: Testing tadalafil for possible use in vascular cognitive impairment	23
The landscape of metabolic brain alterations in Alzheimer's disease	23
Longitudinal association of apolipoprotein E and sleep with incident dementia	23
MicroRNA expression in extracellular vesicles as a novel blood‐based biomarker for Alzheimer's disease	22
Plasma amyloid β levels are driven by genetic variants near APOE, BACE1, APP, PSEN2: A genome‐wide association study in over 12,000 non‐demented participants	22
Mechanisms of motoric cognitive risk—Hypotheses based on a systematic review and meta‐analysis of longitudinal cohort studies of older adults	22
Stability in BMI over time is associated with a better cognitive trajectory in older adults	22
The temporal onset of the core features in dementia with Lewy bodies	22
Early prediction of Alzheimer's disease and related dementias using real‐world electronic health records	22
Amyloid‐beta is present in human lymph nodes and greatly enriched in those of the cervical region	22
Menopause hormone therapy significantly alters pathophysiological biomarkers of Alzheimer's disease	22
Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging	22
What would a population‐level approach to dementia risk reduction look like, and how would it work?	22
Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer's disease: Associations with Aβ‐PET, neurodegeneration, and cognition	22
INPP5D deficiency attenuates amyloid pathology in a mouse model of Alzheimer's disease	22
Plasma biomarkers identify older adults at risk of Alzheimer's disease and related dementias in a real‐world population‐based cohort	22
Differential diagnosis of amnestic dementia patients based on an FDG‐PET signature of autopsy‐confirmed LATE‐NC	22
Education, but not occupation, is associated with cognitive impairment: The role of cognitive reserve in a sample from a low‐to‐middle‐income country	22
An ultra‐sensitive immunoassay detects and quantifies soluble Aβ oligomers in human plasma	21
Artificial intelligence for diagnostic and prognostic neuroimaging in dementia: A systematic review	21
Results and insights from a phase I clinical trial of Lomecel‐B for Alzheimer's disease	21
Genetic risk, adherence to a healthy lifestyle, and cognitive decline in African Americans and European Americans	21
	21
New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia	21
Association of resting heart rate with cognitive decline and dementia in older adults: A population‐based cohort study	20
Diagnostic accuracy of the Cogstate Brief Battery for prevalent MCI and prodromal AD (MCI A+T+) in a population‐based sample	20
Accuracy of the Montreal Cognitive Assessment tool for detecting mild cognitive impairment: A systematic review and meta‐analysis	20
Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers	20
Priorities for research on neuromodulatory subcortical systems in Alzheimer's disease: Position paper from the NSS PIA of ISTAART	20
Prevalence of Alzheimer's disease dementia in the 50 US states and 3142 counties: A population estimate using the 2020 bridged‐race postcensal from the National Center for Health Statistics	20
Neuropsychological, neuropsychiatric, and quality‐of‐life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study	20
APOE genotype, hippocampus, and cognitive markers of Alzheimer's disease in American Indians: Data from the Strong Heart Study	20
Expanding the use of brief cognitive assessments to detect suspected early‐stage cognitive impairment in primary care	20
Why the cognitive “fountain of youth” may be upstream: Pathways to dementia risk and resilience through social connectedness	20
Neuropathological correlates of neuropsychiatric symptoms in dementia	20
Traumatic brain injury and post‐traumatic stress disorder are not associated with Alzheimer's disease pathology measured with biomarkers	20
Plasma p‐tau181 shows stronger network association to Alzheimer's disease dementia than neurofilament light and total tau	20
Attention‐deficit/hyperactivity disorder and Alzheimer's disease and any dementia: A multi‐generation cohort study in Sweden	20
Alzheimer's disease as an innate autoimmune disease (AD2): A new molecular paradigm	20